Reimer J, Gilg K, Karow A, Esser J, Franke G H
Department of Psychiatry and Psychotherapy, University of Hamburg, Hamburg.
Acta Neurol Scand. 2005 Jan;111(1):64-70. doi: 10.1111/j.1600-0404.2004.00357.x.
Health-related quality of life (HRQL) has become an important outcome criterion of medical interventions, but was hardly studied in patients with facial spasms.
Patients with blepharospasm or hemifacial spasm treated with botulinum toxin were included. A healthy control group sociodemografically matched to patients was established. Instruments applied included the SF-36 (global HRQL), the NEI-VFQ (disease-specific HRQL) and the Blepharospasm Rating/Disability Scale, the latter to patients only.
Thirty-one patients with blepharospasm and 21 patients with hemifacial spasm took part. The Blepharospasm Rating/Disability Scale revealed minor functional limitations, but identified some symptoms to be improved. In both patient groups global (both SF-36 Component Summaries) and disease-specific (eight of 12 subscales) HRQL were significantly impaired compared with controls.
HRQL should be integrated as core outcome criterion in treatment of patients with facial spasms. Assessment by a generic and a disease-specific instrument is recommended.
健康相关生活质量(HRQL)已成为医学干预的一项重要结果标准,但在面肌痉挛患者中鲜有研究。
纳入接受肉毒杆菌毒素治疗的眼睑痉挛或半面痉挛患者。建立一个在社会人口统计学方面与患者匹配的健康对照组。所应用的工具包括SF-36(总体HRQL)、NEI-VFQ(疾病特异性HRQL)以及仅用于患者的眼睑痉挛评定/残疾量表。
31例眼睑痉挛患者和21例半面痉挛患者参与研究。眼睑痉挛评定/残疾量表显示功能受限较轻,但确定了一些有待改善的症状。与对照组相比,两个患者组的总体(SF-36两个分量表总分)和疾病特异性(12个分量表中的8个)HRQL均显著受损。
HRQL应作为面肌痉挛患者治疗的核心结果标准纳入考量。建议采用通用和疾病特异性工具进行评估。